Comparing two treatments for AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new medicine called etentamig against a standard combination therapy (Dara-CyBorD) for people with AL amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see which treatment better controls the disease and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of AL amyloidosis, shown by a biopsy of an organ (not the bone marrow).
- You must have signs of abnormal plasma cells in your blood or bone marrow.
- Your free light chain levels (a blood test) must be at least 50 mg/L difference.
- You must not have had any prior treatment for amyloidosis.
- The disease must be affecting at least one organ, and you must be in a certain cardiac risk stage (1, 2, 3a, or 3b for the randomized part).
- You should be able to care for yourself (performance status 0-2) and not have active hepatitis B or C, or other cancers in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Hear when a new Amyloid Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.